Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Gross Margin

Rigel Pharmaceuticals Gross Margin Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Gross Margin from 2010 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Rigel Pharmaceuticals Gross Margin for the quarter ending June 06, 2020 was $10m a -205.85% decrease of -20m year over year
  • Rigel Pharmaceuticals Gross Margin for the last 12 months ending June 06, 2020 was $44m a 21.81% increase of 10m year over year
  • Rigel Pharmaceuticals Annual Gross Margin for 2019 was $9m a 164.97% increase of 15m from 2018
  • Rigel Pharmaceuticals Annual Gross Margin for 2018 was $-6m a -15,370.55% increase of 926m from 2017
  • Rigel Pharmaceuticals Annual Gross Margin for 2017 was $-932m a 77.33% decrease of -721m from 2016
Other Margins & Efficiency Metrics:
  • Rigel Pharmaceuticals EBITDA Margin for the quarter ending December 12, 2018 was $7m a 801.93% increase of 57m year over year
  • Rigel Pharmaceuticals Return on Capital % for the quarter ending September 09, 2018 was -53.67 a -55.75% increase of 29.92 year over year
  • Rigel Pharmaceuticals Return on Equity % for the quarter ending September 09, 2018 was -83.74 a -57.61% increase of 48.24 year over year
View Chart On Koyfin

Quarterly RIGL Gross Margin Data

06/2020$10m
03/2020$71m
12/2019$6m
09/2019$29m
06/2019$-30m
03/2019$12m
12/2018$63m
09/2018$-130m
06/2018$-506m
09/2017$-1,101m

Annual RIGL Gross Margin Data

2019$9m
2018$-6m
2017$-932m
2016$-211m
2015$-117m
2014$-721m
2013$-954m
2012$-3,401m
2011$-1,360m
2010$62m